A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Additional locations may be listed on ClinicalTrials.gov for NCT03600883.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationAmgen, Inc.

• Primary ID20170543
• Secondary IDsNCI-2018-01725
• ClinicalTrials.gov IDNCT03600883